PTC518 was granted Fast Track designation based off strong 12-month interim data on safety and efficacy.

Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...

GE HealthCare has received approval for Flyrcado, its enhanced diagnosis tool for coronary heart disease, from the Food and Drug Administration. The company said on Friday that Flyrcado, or ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

The FDA claimed these clinics were plying patients with an illegal drug derived from their stem cells. A federal court agrees ...

A new law goes into effect in Louisiana on Oct. 1 that reclassifies mifepristone and misoprostol as "controlled dangerous ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. In a new ...

In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...

A new law will go into effect in Louisiana on Oct. 1 that will classify two drugs—mifepristone and misoprostol, which are ...

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...